Ministry Medical Group at Saint Mary's Hospital
Welcome,         Profile    Billing    Logout  
 8 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bseiso, Ali W
EQUATE, NCT04566328: Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the Trial

Recruiting
3
1450
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Daratumumab and Hyaluronidase-fihj, DARA Co-formulated with rHuPH20, DARA/rHuPH20, Daratumumab + rHuPH20, Daratumumab with rHuPH20, Daratumumab-rHuPH20, Daratumumab/Hyaluronidase-fihj, Daratumumab/rHuPH20 Co-formulation, Darzalex Faspro, Darzalex/rHuPH20, HuMax-CD38-rHuPH20, Recombinant Human Hyaluronidase Mixed with Daratumumab, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Quality-of-Life Assessment, Quality of Life Assessment
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
12/27
12/27
DETER-SMM, NCT03937635: Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Recruiting
3
288
US
Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Smoldering Plasma Cell Myeloma
12/29
12/29
ECOG-ACRIN EA9171, NCT03516279: Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Recruiting
2
40
US
Dasatinib, BMS-354825, Sprycel, Imatinib Mesylate, CGP 57148, CGP57148B, Gleevec, Glivec, STI 571, STI-571, STI571, Laboratory Biomarker Analysis, Nilotinib, AMN 107, Tasigna, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
08/28
08/31

Download Options